CLDI Calidi Biotherapeutics: Bozor kapitallashuvining balans qiymatiga nisbati

calidibio.com (CLDI) - korporativ logo

Calidi Biotherapeutics (CLDI) kompaniyasining bozor qiymatining buxgalteriya qiymatiga nisbati dinamikasi antitumor agentlarini maqsadli yetkazib berish uchun stam hujayralaridan foydalanish bilan bog'liq. 0.42 qiymati ushbu metrikaning joriy darajasini ifodalaydi. Xarajatlarni optimallashtirish ishlab chiqarishni cGMP ob'ektlariga autsorsing qilish orqali amalga oshiriladi. Barqaror boshqaruv global tibbiyot markazlari bilan strategik aloqalarni rivojlantirish orqali aksiyadorlarning ishonchini mustahkamlaydi.

Calidi Biotherapeutics, Inc. (CLDI) - Bozor kapitallashuvining balans qiymatiga nisbati 21.02.2024dan 27.10.2026gacha

CLDI (Calidi Biotherapeutics): tahliliy kesimlar va indikatorlar boʻyicha maʼlumotlar

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya narxi calidibio.com|CLDI - Tahlilchilar median maqsadi
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor kapitallashuvi Calidi Bio|CLDI - Kompaniyani butunlay sotib olishdagi haqiqiy narx
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya hisobiga balans qiymati Calidi Biotherapeutics|CLDI - Balans kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati calidibio.com|CLDI - Biznesning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Umumiy qarzning kapitalga nisbati Calidi Biotherapeutics|CLDI - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati calidibio.com|CLDI - Kompaniyaning umumiy yig'indi qarzi|Qarzning balans kapitallashuviga nisbati Calidi Bio
Fundamental baholash:CLDI (Calidi Biotherapeutics Inc.)
Calidi Biotherapeutics tayyor mahsulotlari

Calidi Biotherapeutics onkolitik viruslardan foydalangan holda qattiq o'smalar uchun inqilobiy davolash usullarini ishlab chiqishga e'tibor qaratadi. Ushbu ko'rsatkich biznesning joriy bozor qiymatini uning sof balans qiymati bilan solishtiradi. Narx-balans ko'rsatkichi tendentsiyasini tahlil qilish orqali investor bozor kompaniyani qanchalik hadda haddan tashqari baholaganini aniqlaydi. Bioteknologiya sektorida yuqori premium kelgusidagi sug'urta to'lovlariga bo'lgan kutishlarni aks ettiradi. Aktiv yuqori xavfli spekulyativ instrument sifatida tasniflanadi.

Asosiy raqobatchilar

BeiGene Ltd - Bozor kapitallashuvining balans qiymatiga nisbati|halozyme.com (HALO) - Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati RVMD|Kapitallashuvning sof aktivlarga nisbati Ascentage Pharma Group International|Bozor kapitallashuvining balans qiymatiga nisbati CGON|Bozor kapitallashuvining balans qiymatiga nisbati URGN (UroGen Pharma Corp)|BCAX - Bozor qiymatining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati personalis.com PSNL|ERAS: Bozor kapitallashuvining balans qiymatiga nisbati|DCTH - Kapitallashuvning sof aktivlarga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati YMAB|AURA (Aura Corp) - Bozor qiymatining balans qiymatiga koeffitsiyenti|CADL - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati accuray.com (ARAY)|SELLAS Life Sciences (SLS) - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati Actuate Therapeutics Inc. (ACTU)|Citius Oncology, Inc - Bozor kapitallashuvining balans qiymatiga nisbati|HURA - Kapitallashuvning sof aktivlarga nisbati|Protara Therapeutics - Kapitallashuvning sof aktivlarga nisbati|FATE: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati aadibio.com WHWK|TScan Therapeutics, Inc. (TCRX) - Balans qiymatiga nisbatan bozor qiymati|Bozor kapitallashuvining balans qiymatiga nisbati CSBR (Champions Oncology Inc)|Bozor qiymatining balans qiymatiga koeffitsiyenti XBiotech USA|Bozor kapitallashuvining balans qiymatiga nisbati CVM (CEL-SCI Corporation)|Kapitallashuvning sof aktivlarga nisbati ostherapies.com (OSTX)|Bozor kapitallashuvining balans qiymatiga nisbati RADX (Radiopharm Theranostics)|Artiva Biotherapeutics Inc. - Bozor kapitallashuvining balans qiymatiga nisbati|ANL - Bozor qiymatining balans qiymatiga nisbati|VERU - Bozor qiymatining balans qiymatiga nisbati|Tempest Therapeutics - Bozor kapitallashuvining balans qiymatiga nisbati|Xilio Therapeutics (XLO) - Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati Renovaro Biosciences (RENB)|Kapitallashuvning balans qiymatiga nisbati Mural Bio|KAPA (Kairos Pharma Ltd) - Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi onkuretherapeutics.com OKUR|Kapitallashuvning sof aktivlarga nisbati CytoMed Therapeutics Limited|Balans qiymatiga nisbatan bozor qiymati Curis Inc. CRIS|APLM - Bozor kapitallashuvining balans qiymatiga nisbati|THAR - Bozor qiymatining balans qiymatiga nisbati|advanbiomed.com - Bozor kapitallashuvining balans qiymatiga nisbati|GNPX (Genprex Inc) - Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati SBFM (Sunshine Biopharma)|Bozor qiymatining balans qiymatiga koeffitsiyenti Xenetic Bio (XBIO)|Kapitallashuvning sof aktivlarga nisbati Salarius Pharmaceuticals, Inc.|Bozor kapitallashuvining balans qiymatiga multiplikatori Purple Biotech Ltd (PPBT)|Bozor kapitallashuvining balans qiymatiga nisbati American Oncology Network, Inc.|Balans qiymatiga nisbatan bozor qiymati BeiGene Ltd BGNE|CKPT (Checkpoint Therapeutics) - Bozor kapitallashuvining balans qiymatiga nisbati|ELEV: Bozor qiymatining balans qiymatiga koeffitsiyenti|Bozor qiymatining balans qiymatiga nisbati icadmed.com ICAD|Ikena Oncology (IKNA) - Balans qiymatiga nisbatan bozor qiymati|NTBL (Notable Labs Inc.) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati VIRX|MOR - Bozor qiymatining balans qiymatiga nisbati|Sof aktivlarga nisbatan bozor kapitallashuvi nayabiosciences.com (NAYA)|AAPGV: Bozor kapitallashuvining balans qiymatiga nisbati